• Explore /
  • Poster
  • / Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.

Safety profile of immune checkpoint inhibitors versus sorafenib as first-line treatment in advanced hepatocellular carcinoma: A meta-analysis of randomized controlled trials.

Abstract Poster

Authors

null

Alessandro Rizzo

Department of Experimental, Diagnostic, and Specialty Medicine–DIMES, Sant'Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy

Alessandro Rizzo , Giorgio Frega , Angela Dalia Ricci , Andrea Palloni , Simona Tavolari , Giovanni Brandi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session: Hepatobiliary Cancer

Track

Hepatobiliary Cancer

Sub Track

Therapeutics

Citation

J Clin Oncol 39, 2021 (suppl 3; abstr 315)

DOI

10.1200/JCO.2021.39.3_suppl.315

Abstract #

315

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Danni Li

First Author: Jaekyung Cheon

First Author: Anthony B. El-Khoueiry

First Author: Jaekyung Cheon